Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + trastuzumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- ALX Oncology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of **evorpacept** (ALX148), **trastuzumab** (Herceptin), and **gemcitabine** (Gemzar). Evorpacept is a high-affinity CD47-blocking fusion protein designed to enhance immune-mediated cancer cell elimination by blocking the "don't eat me" signal from CD47, thereby promoting phagocytosis of tumor cells. Trastuzumab is a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2/ERBB2) to inhibit proliferation of HER2-overexpressing tumor cells and mediate antibody-dependent cellular cytotoxicity (ADCC). Gemcitabine is a deoxycytidine analog antimetabolite which incorporates into DNA during replication, causing masked DNA chain termination and apoptosis in dividing cancer cells. This triple combination is under investigation for HER2-positive metastatic breast cancer and other advanced solid tumors, aiming to synergistically promote tumor cell death through immune and cytotoxic mechanisms[7][10][3][9][6].
- Other names
- evorpacept + trastuzumab + gemcitabine
02
Targets
SIRPA (Signal-regulatory protein alpha)CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on evorpacept + trastuzumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + trastuzumab + gemcitabine.